Highly bioavailable silibinin nanoparticles inhibit HCV infection.
Liu CH, Lin CC, Hsu WC, Chung CY, Lin CC, Jassey A, Chang SP, Tai CJ, Tai CJ, Shields J, Richardson CD, Yen MH, Tyrrell DLJ, Lin LT.
Liu CH, et al.
Gut. 2017 Oct;66(10):1853-1861. doi: 10.1136/gutjnl-2016-312019. Epub 2016 Jul 19.
Gut. 2017.
PMID: 27436270